Access Bio엑세스바이오
950130 · KOSDAQ · ₩950130 · 엑세스바이오
₩1,920▼ ₩40 (2.04%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | −134.9% | −78.2% | 47.7% | 48.8% | 79.3% | 78.5% |
| Operating margin | −302.5% | −202.7% | −3.8% | 6.2% | 45.4% | 51.5% |
| Net margin | −474.1% | −262.7% | −0.3% | −0.9% | 33.5% | 37.6% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −26.4% | −73.3% | −69.1% | −66.6% | +81.3% | — |
| Operating income growth | −9.9% | −1,336.4% | −118.8% | −95.4% | +59.8% | — |
| Net income growth | −32.8% | −22,558.5% | +89.5% | −100.9% | +61.9% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −20.9% | −13.9% | −0.1% | −0.5% | 73.6% | 68.6% |
| Return on assets | −18.3% | −12.6% | −0.2% | −0.7% | 50.5% | 44.5% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 14.8% | 8.9% | 13.6% | 17.7% | 41.4% | 52.4% |
| Net debt to equity | −35.2% | −55.3% | −50.2% | −53.1% | −73.6% | −49.3% |
| Current ratio | 695.2% | 1,742.4% | 1,238.1% | 950.6% | 364.6% | 237.4% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Access Bio / 엑세스바이오 / 950130 / KRX:950130
Source: KRX statistical information